Freenome
Early Cancer Detection Through Blood
About Freenome
Funding & Growth
✓ Pros
- • Mission-driven (early cancer detection)
- • Strong funding and partnerships (Roche, Exact Sciences)
- • Cutting-edge multiomics and ML
- • Bay Area biotech hub location
- • Going public in 2026 (equity upside)
✗ Cons
- • Pre-commercial stage (first IVD launching 2026)
- • Competitive liquid biopsy market
- • High-growth pace can be demanding
- • Brisbane location (south of SF)
🏢 Working Here
Freenome is developing blood tests for early cancer detection using a multiomics platform that combines tumor and non-tumor signals with machine learning.
The company has raised over $1.4B from top healthcare investors and has partnerships with Roche and Exact Sciences.
Teams collaborate across clinical, scientific, and computational specialties.
The Brisbane headquarters is in the SF Bay Area biotech corridor.
Freenome plans to go public in 2026 via SPAC merger and launch its first colorectal cancer screening test.
🧬 Bioinformatics Focus
Freenome's computational work centers on:
- Multiomics Integration - Combining cfDNA, methylation, protein, and immune signals from blood samples.
- Machine Learning - Deep learning models trained on billions of biomarkers to detect cancer patterns.
- NVIDIA Partnership - Accelerated AI/DL for multi-cancer detection.
- Clinical Validation - Large-scale clinical studies with thousands of patients.
📈 Career Growth & Development
Development
As Freenome transitions from R&D to commercialization, opportunities span research, clinical development, and regulatory affairs.
Career Tracks
Scientists can grow through IC tracks or move into leadership.
Overview
The upcoming IPO creates equity upside potential.